Cardiol Therapeutics Inc Class A (CRDL.TO) has seen a notable decline in its stock price this week amidst significant corporate developments.
This week, Cardiol Therapeutics Inc Class A (CRDL.TO) experienced a price drop of 12.32%, closing at C$1.78 on Tuesday. The market's reaction reflects investor sentiment following various corporate announcements and recent performance metrics.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$216.29M
52W high
$3.23
52W low
$1.23
1W change
-12.32%
Beta
0.72
Analyst Price Targets
Based on analyst covering CRDL · as of Oct 12, 2026
Wall Street analysts forecast CRDL stock price to rise 469.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.00
+469.1% Upside
Previously C$6.00 on Sep 17, 2026
Current Price
C$1.23
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
68.8%
Annualized
90-Day Vol
65.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.13
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.89 | C$1.49 – C$2.39 |
| 60 trading days | C$2.01 | C$1.43 – C$2.80 |
| 90 trading days | C$2.13 | C$1.41 – C$3.21 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the implications of the recent corporate developments and the company's financial health as they evaluate their positions in Cardiol Therapeutics.
Cardiol Therapeutics' Stock Down 12.32% This Week Amidst Mixed Corporate Developments.
The stock's performance reflects a broader trend of volatility, with a 1-month decline of 43.67% and a year-to-date increase of 30.88%.
Bull case
The company has met its Phase III MAVERIC trial enrollment target ahead of schedule. This progress in its clinical studies could improve its valuation if the trials succeed.
Bear case
Despite the positive news about trial enrollment, the stock has dropped significantly over the past month. This decline raises concerns about investor confidence and the company's financial sustainability.
Recent Price Action
Advertisement
Cardiol Therapeutics' stock closed at C$1.78 on Tuesday, reflecting a decline of 3.78% for the day. Over the past week, the stock has dropped 12.32%, continuing a trend of volatility that has seen a 1-month decrease of 43.67%. Despite this downturn, the stock is still up 30.88% year-to-date.
Corporate Developments
Cardiol Therapeutics has made headlines recently with several key announcements. On September 23, 2026, the company achieved its Phase III MAVERIC trial enrollment target ahead of schedule and plans to expand the study to include more patients. Additionally, the company disclosed that it received over USD $7 million from warrant exercises, which will help extend its cash runway into 2028. These developments are critical for investors to consider, as they may influence the company's future performance.
Technical Picture
From a technical standpoint, Cardiol Therapeutics' stock is trading below both its 50-day moving average (C$2.45) and its 200-day moving average (C$1.79), indicating bearish momentum. The stock is currently at 28% of its 52-week range, which spans from C$1.23 to C$3.23. The stock's beta of 0.72 suggests lower volatility compared to the broader market. Recent trading volume has been below average, with the latest volume at 179,622 shares compared to a 20-day average of 285,607 shares, indicating reduced trading interest.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
